Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

By sjmartinez • February 17, 2023

Garassino MC, Gadgeel S, Novello S, Halmos B, Felip E, Speranza G, Hui R, Garon EB, Horinouchi H, Sugawara S, Rodriguez-Abreu D, Reck M, Cristescu R, Aurora-Garg D, Loboda A, Lunceford J, Kobie J, Ayers M, Piperdi B, Pietanza MC, Paz-Ares L. Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC. JTO Clin Res Rep. 2022 Nov 8;4(1):100431. doi: 10.1016/j.jtocrr.2022.100431. PMID: 36793385; PMCID: PMC9923193.

Tags: Biomarker, Hematology/Oncology, Metastatic non‒small-cell lung cancer, pembrolizumab, Publications, Single-gene genetic alterations, Tissue tumor mutational burden

Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]

Wu YL, Majem M, John T, Grohé C, Wang J, Goldman JW, Lu S, Shepherd FA, Wang Q, Kato T, Aokage K, Zhong WZ, Laktionov[...]

Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma

Paniker AG, Marshalek JP, Chao E, Yashar D, Tomassetti S. Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma. J Hematol. 2026 Aug 31;15(4):188-197.[...]

Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank

Msaouel P, La Rosa S, Abel EJ, Albiges L, Barata PC, Berg SA, Braun DA, Brugarolas J, Campbell MT, Carlo MI, Coleman K, Cost NG,[...]